MannKind (MNKD) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Portfolio and capital deployment
Portfolio spans United Therapeutics royalties and manufacturing, AFREZZA, FUROSCIX, and the inhaled nintedanib pipeline.
Management expects profitability in Q4 2026 and for 2027, following a year of investment for growth; capital may fund pipeline development, existing products, M&A, or debt reduction.
United Therapeutics-related royalties, milestones, and manufacturing are expected to generate over $1B in revenue through 2030.
Future business development focus includes nephrology, cardiology, endocrinology, pulmonary and respiratory areas, and complex drug-device combinations beyond inhalation.
FUROSCIX and ReadyFlow
ReadyFlow received approval in Q3 2026; within its first six weeks, nearly 75%-80% of patients converted from the on-body infusor, several quarters ahead of expectations.
Management expects Q4 2026 to be the strongest quarter ever for ReadyFlow and the overall business.
ReadyFlow is positioned to expand FUROSCIX use into hospitals; management cited heart failure or fluid overload as accounting for 40%-50% of hospitalizations.
A 40 mg presentation could broaden prescribing among more cautious physicians, while aggressive diuresis users may favor 120 mg or 160 mg doses.
2027 FUROSCIX indicators will include prescriber count, breadth of prescribing, and use in hospital versus retail or community settings.
United Therapeutics partnership and DPI platform
United Therapeutics is advancing TYVASO DPI and pulmonary fibrosis opportunities, with PPF next; management sees the collaboration as having potential to continue for another decade or two.
IPF is expected to launch first with nebulized delivery, potentially in 2027; a DPI may support compliance and market expansion, subject to future development.
MannKind's IPF powder study showed tolerability, with cough not prompting discontinuations, supporting confidence in DPI use for future phase III development.
Manufacturing capacity for TYVASO has been scaled with United Therapeutics; the nintedanib program is already manufactured at scale, with filling equipment in place and lower incremental capital needs.
The DPI platform uses FDKP to carry drug payloads; formulations vary by product, while the inhaler is designed to slow powder delivery and reduce dependence on inhalation effort.
Latest events from MannKind
- ReadyFlow momentum and pipeline expansion underpin growth into 2027 and beyond.MNKD
Jefferies Global Healthcare Conference - Q3 revenue rose 24% as commercial launches advanced, with Q4 profitability expected.MNKD
Q3 2026 - IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification.MNKD
Chardan's 10th Annual Healthcare Conference - Afrezza pediatric launch, FUROSCIX ReadyFlow, and IPF 201 progress drive growth focus.MNKD
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue up 43% to $109.4M, driven by Afrezza pediatric and FUROSCIX launches.MNKD
Q2 2026 - Nintedanib DPI showed strong safety and efficient lung delivery in IPF, supporting Phase 2 trials.MNKD
Study result - FDA approved FUROSCIX ReadyFlow, enabling rapid at-home IV-equivalent diuretic therapy.MNKD
FDA announcement - Q4 and FY 2025 revenues surged, driven by FUROSCIX and Afrezza, with major 2026 catalysts ahead.MNKD
Q4 2025 - Q1 revenue up 18% to $78.4M, net income up 24%, driven by Tyvaso DPI and Afrezza growth.MNKD
Q1 2025